LOVELAND, Colo., Nov. 15, 2010 /PRNewswire-FirstCall/ — Heska
Corporation (Nasdaq: HSKA, “Heska” or the “Company”) today reported
financial results for its third quarter ended September 30,
2010.
(Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)
“These results exceed our revenue expectations and most recent
revenue guidance. We had a particularly strong quarter in our
Other Vaccines, Pharmaceuticals and Products segment where the USDA
validated an improved process for our line of cattle vaccines,
allowing us to ship a significant quantity of product in a category
which had previously been on hold due to regulatory discussions,”
said Robert Grieve, Heska’s Chairman and CEO. “As we
have reported over the course of 2010, we faced a difficult
year-over-year comparison in our Core Companion Animal Health
segment as we are no longer selling the old line of handheld blood
analysis instruments and affiliated consumables. This product
area accounted for over $2.7 million in revenue in the third
quarter of 2009, with no such revenue in the third quarter of
2010.”
Investor Conference CallManagement will conduct a conference
call on Monday, November 15, 2010 at 9:00 a.m. MST (11:00 a.m.
EST) to discuss the third quarter 2010 financial results. To
participate, dial (800) 762-8779 (domestic) or (480) 629-9771
(international); the conference call access number is 4371990.
The conference call will also be broadcast live over the
Internet at http://www.heska.com. To
listen, simply log on to the web at this address at least ten
minutes prior to the start of the call to register, download and
install any necessary audio software. Telephone replays
‘/>”/>
SOURCE
